Nerve-Sparing radiation may help men keep sexual function after prostate cancer treatment

NCT ID NCT03525262

Ongoing Symptom relief Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version that spares these nerves. The main goal is to see if the nerve-sparing approach leads to less decline in erectile function, while still controlling the cancer effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing
What this could lead to: If successful, this approach could help men with prostate cancer maintain sexual function after radiotherapy without compromising cancer treatment.
What could go wrong: This is a phase 2 trial with only 124 participants, so results may not apply to everyone. The nerve-sparing technique might not preserve function as hoped, or could increase the risk of cancer recurrence in the spared area.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Penn Medicine Radiation Oncology

Philadelphia, Pennsylvania, 19104, United States
Penrose Hospital

Colorado Springs, Colorado, 80907, United States
Stony Brook University Cancer Center

Stony Brook, New York, 11794, United States
UCSF ( Department of Radiation Oncology University of California San Francisco)

San Francisco, California, 94143, United States
UT Southwestern Cancer Center

Dallas, Texas, 75235, United States
University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Michigan- Michigan Medicine

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.